No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $338
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps
Alnylam Pharmaceuticals Shares Are Trading Higher After the Company Secured FDA Approval Pf SNDA for Its RNAi Therapeutic, AMVUTTRA ,for Treatment of ATTR-CM in Adults.
CDC Vaccine Meeting, Delayed Under RFK Jr., Is Rescheduled
Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target
Alnylam Pharmaceuticals Analyst Ratings